

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 83874

**Title:** Advanced gastric cancer achieving major pathologic regression after chemoimmunotherapy combined with hypofractionated radiotherapy: A case report

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 03731081

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Professor

**Reviewer's Country/Territory:** Russia

**Author's Country/Territory:** China

**Manuscript submission date:** 2023-02-19

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2023-02-19 17:27

**Reviewer performed review:** 2023-02-20 07:50

**Review time:** 14 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Novelty of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
Creativity or innovation of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation

<b>Scientific significance of the conclusion in this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

## SPECIFIC COMMENTS TO AUTHORS

The authors presented in the manuscript a very interesting clinical case of successful treatment of stage 4 gastric cancer since May 12, 2023. They used an innovative combined treatment method of chemotherapy, radiation therapy, immunotherapy and gastrectomy. The manuscript meets the requirements of evidence-based medicine. The positive dynamics of the patient as a result of treatment has been convincingly confirmed. This combination therapy is worthy of further exploration, and also needs long-term follow-up of patients. Recommended for publication in the World Journal of Gastrointestinal Oncology or the World Journal of Clinical Cases.

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 83874

**Title:** Advanced gastric cancer achieving major pathologic regression after chemoimmunotherapy combined with hypofractionated radiotherapy: A case report

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05626712

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Academic Editor, Academic Research, Assistant Professor, Attending Doctor, Research Scientist

**Reviewer's Country/Territory:** Iran

**Author's Country/Territory:** China

**Manuscript submission date:** 2023-02-19

**Reviewer chosen by:** Geng-Long Liu

**Reviewer accepted review:** 2023-03-12 03:08

**Reviewer performed review:** 2023-03-21 12:41

**Review time:** 9 Days and 9 Hours

Scientific quality	<input checked="" type="radio"/> Grade A: Excellent <input type="radio"/> Grade B: Very good <input type="radio"/> Grade C: Good <input type="radio"/> Grade D: Fair <input type="radio"/> Grade E: Do not publish
Novelty of this manuscript	<input type="radio"/> Grade A: Excellent <input checked="" type="radio"/> Grade B: Good <input type="radio"/> Grade C: Fair <input type="radio"/> Grade D: No novelty

<b>Creativity or innovation of this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation
<b>Scientific significance of the conclusion in this manuscript</b>	<input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

## SPECIFIC COMMENTS TO AUTHORS

Summary: A valuable case report on a dramatic response of a deadly, advanced gastric cancer to a combination of chemotherapy, immunotherapy, and radiotherapy.

General evaluation: Valuable in terms of clinical implication. Comments to improve:

1. Abstract-Case summary: Please name the chemotherapy and immunotherapy agents. Besides, please mention the radiotherapy regimen (including dose, fraction numbers, clinical target volume, and schedule).
2. Abstract-Case summary: It is recommended to update the pathological response per the standard iRECIST criteria. This comment also include the main text.
3. Abstract-Case summary: Please mention the interval duration (in months) of recurrence-free survival.
4. Please explain the acronyms for their first presentation in either Abstract and Main text.
5. Page 3-line 12: please mention the cut-off point of high tumor mutation burden in gastric cancer. Is 5.98 muts/MB high-TMB or low-TMB?
6. Page 4-line 2: Please mention the interval between

treatment and the follow-up PET-CT scan. 7. Discussion: Case reports are clues for clinical and research studies. The presented case experienced dramatic response to chemoimmunotherapy in combination with radiotherapy. It is expected the Discussion section explains the putative mechanisms involved in this dramatic response. Recent evidence has put forward the importance of cancer mitochondrial metabolism in response to either radiotherapy and immunotherapy. Recently, Houshyari et al. noted that enhanced mitochondrial metabolism can enhance the response to anti-PD1 agents by downregulating the PD-1 expression on immune cells and providing prerequisite for the prolonged anti-tumor response (<https://pubmed.ncbi.nlm.nih.gov/36469835/>). Another study highlighted the importance of mitochondria biogenesis in response to radiotherapy (<https://pubmed.ncbi.nlm.nih.gov/36719474/>). This study noted that enhanced mitochondrial metabolism can improve tumor response through activating the 6th R of radiobiology, the Reactivation. It is recommended the authors mention this correlation using the noted references.

## RE-REVIEW REPORT OF REVISED MANUSCRIPT

**Name of journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 83874

**Title:** Advanced gastric cancer achieving major pathologic regression after chemoimmunotherapy combined with hypofractionated radiotherapy: A case report

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05626712

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Academic Editor, Academic Research, Assistant Professor, Attending Doctor, Research Scientist

**Reviewer's Country/Territory:** Iran

**Author's Country/Territory:** China

**Manuscript submission date:** 2023-02-19

**Reviewer chosen by:** Yu-Lu Chen

**Reviewer accepted review:** 2023-04-13 06:31

**Reviewer performed review:** 2023-04-13 06:42

**Review time:** 1 Hour

<b>Scientific quality</b>	<input checked="" type="radio"/> Grade A: Excellent <input type="radio"/> Grade B: Very good <input type="radio"/> Grade C: Good <input type="radio"/> Grade D: Fair <input type="radio"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="radio"/> Grade A: Priority publishing <input type="radio"/> Grade B: Minor language polishing <input type="radio"/> Grade C: A great deal of language polishing <input type="radio"/> Grade D: Rejection
<b>Conclusion</b>	<input checked="" type="radio"/> Accept (High priority) <input type="radio"/> Accept (General priority) <input type="radio"/> Minor revision <input type="radio"/> Major revision <input type="radio"/> Rejection



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="checkbox"/> ] Anonymous [ <input type="checkbox"/> ] Onymous Conflicts-of-Interest: [ <input type="checkbox"/> ] Yes [ <input checked="" type="checkbox"/> ] No
-------------------------------------	---

#### **SPECIFIC COMMENTS TO AUTHORS**

Thanks the authors for addressing all my comments. I have no more comments.  
Congratulations to authors for this valuable work. Hope it helps to improve the patients'  
treatment in near future.